26 related articles for article (PubMed ID: 38608693)
1. Tumor metabolism in pheochromocytomas: clinical and therapeutic implications.
Jeeyavudeen MS; Mathiyalagan N; Fernandez James C; Pappachan JM
Explor Target Antitumor Ther; 2024; 5(2):349-373. PubMed ID: 38745767
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial.
Campbell MT; Balderrama-Brondani V; Jimenez C; Tamsen G; Marcal LP; Varghese J; Shah AY; Long JP; Zhang M; Ochieng J; Haymaker C; Habra MA
Lancet Oncol; 2024 May; 25(5):649-657. PubMed ID: 38608694
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
Apolo AB; Nadal R; Tomita Y; Davarpanah NN; Cordes LM; Steinberg SM; Cao L; Parnes HL; Costello R; Merino MJ; Folio LR; Lindenberg L; Raffeld M; Lin J; Lee MJ; Lee S; Alarcon SV; Yuno A; Dawson NA; Allette K; Roy A; De Silva D; Lee MM; Sissung TM; Figg WD; Agarwal PK; Wright JJ; Ning YM; Gulley JL; Dahut WL; Bottaro DP; Trepel JB
Lancet Oncol; 2020 Aug; 21(8):1099-1109. PubMed ID: 32645282
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Drilon A; Rekhtman N; Arcila M; Wang L; Ni A; Albano M; Van Voorthuysen M; Somwar R; Smith RS; Montecalvo J; Plodkowski A; Ginsberg MS; Riely GJ; Rudin CM; Ladanyi M; Kris MG
Lancet Oncol; 2016 Dec; 17(12):1653-1660. PubMed ID: 27825636
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Brose MS; Robinson B; Sherman SI; Krajewska J; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Hernando J; Faoro L; Banerjee K; Oliver JW; Keam B; Capdevila J
Lancet Oncol; 2021 Aug; 22(8):1126-1138. PubMed ID: 34237250
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial.
Jimenez C; Habra MA; Campbell MT; Tamsen G; Cruz-Goldberg D; Long J; Bassett R; Dantzer R; Balderrama-Brondani V; Varghese J; Lu Y
Lancet Oncol; 2024 May; 25(5):658-667. PubMed ID: 38608693
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.
Tong A; Li M; Cui Y; Ma X; Wang H; Li Y
Front Endocrinol (Lausanne); 2020; 11():61. PubMed ID: 32132978
[No Abstract] [Full Text] [Related]
9. Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies.
Jasim S; Jimenez C
Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101354. PubMed ID: 31685417
[TBL] [Abstract][Full Text] [Related]
10. Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.
Jimenez P; Tatsui C; Jessop A; Thosani S; Jimenez C
Curr Oncol Rep; 2017 Oct; 19(12):83. PubMed ID: 29081018
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.
Belum VR; Serna-Tamayo C; Wu S; Lacouture ME
Clin Exp Dermatol; 2016 Jan; 41(1):8-15. PubMed ID: 26009777
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
